CMBA
AMED

C.M. Bidwell & Associates’s Amedisys AMED Stock Holding History

C.M. Bidwell & Associates’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-40
Closed -$12K – 501
2020
Q4 		$12K Sell
40
-48
-55% -$12.3K 0.01% 363
2020
Q3 		$21K Sell
88
-20
-19% -$4.55K 0.02% 304
2020
Q2 		$21K Sell
108
-74
-41% -$13.8K 0.02% 298
2020
Q1 		$33K Sell
182
-323
-64% -$57.5K 0.03% 214
2019
Q4 		$84K Sell
505
-85
-14% -$12.6K 0.08% 165
2019
Q3 		$77K Sell
590
-60
-9% -$7.81K 0.08% 205
2019
Q2 		$79K Sell
650
-30
-4% -$3.56K 0.08% 198
2019
Q1 		$84K Sell
680
-770
-53% -$96.6K 0.08% 193
2018
Q4 		$170K Sell
1,450
-415
-22% -$48.9K 0.18% 138
2018
Q3 		$233K Buy
1,865
+340
+22% +$37.5K 0.22% 125
2018
Q2 		$130K Buy
+1,525
New +$112K 0.12% 163
2014
Q4 		– Sell
-7,720
Closed -$156K – 205
2014
Q3 		$156K Buy
+7,720
New +$149K 0.04% 167

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

C.M. Bidwell & Associates's AMED Position: Q1 2021 in Review

C.M. Bidwell & Associates sold out of Amedisys (AMED) in Q1 2021, closing a stake of 40 shares — an estimated $12K sold.

C.M. Bidwell & Associates first reported a position in AMED in Q3 2014 and held it in 12 quarters. The position peaked at $233K in Q3 2018. 388 funds tracked by Wall St. Rank hold AMED as of Q1 2021.

  • C.M. Bidwell & Associates reported no remaining Amedisys position as of Q1 2021 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 40 Amedisys shares in Q1 2021, an estimated $12K.
  • C.M. Bidwell & Associates first reported a position in Amedisys in Q3 2014 and held it in 12 quarters.
  • C.M. Bidwell & Associates's Amedisys position peaked at $233K in Q3 2018.
  • 388 funds tracked by Wall St. Rank held Amedisys as of Q1 2021.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2021, filed 14 May 2021.